Current therapeutic approach to treating heart allotransplantation rejection focus on immunosuppression protocols that carry harmful side effects after chronic use, which include global immune depression to the patient. The present inventors have discovered alternative and synergistic protocols based on inhibiting NF-κB and NLRP3 inflammasome-dependent IL-1β release with nitrated NSAID derivatives.
目前治疗心脏异种移植排斥的方法主要集中在免疫抑制方案上,但长期使用会带来有害副作用,包括对患者的全局免疫抑制。本发明者发现了一种基于抑制NF-κB和NLRP3炎症小体依赖性IL-1β释放的硝化N
SAID衍
生物的替代和协同协议。